Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

Adma Biologics (ADMA) closed at $10.65 in the latest trading session, marking a +1.53% move from the prior day. This move outpaced the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a

Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Adma Biologics (ADMA) Laps the Stock Market: Here's Why

In the latest close session, Adma Biologics (ADMA) was up +1.22% at $9.95. The stock's performance was ahead of the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.58%, while the

Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?

ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Asceniv, its lead product, is a plasma-derived IVIG

Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $9.01, marking a -1.53% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day

Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?

ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Gross margin improved to 57.4% in 2025 from 51.5% in

ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?

ADMA Biologics’ ADMA shares have plunged 42.5% year to date against the industry’s growth of 1.6%.  The stock has also underperformed the sector and the S&P 500 in this time frame.

Much of this

Cansino Biologics Inc.

WKN: A2PGFW / Name: Cansino Biologics Inc. / Stock / ? /

?
2.790%

Mustgrow Biologics Corp.

WKN: A2PNS7 / Name: Mustgrow Biologics Corp. / Stock / ? /

?
0.000%

Pure Biologics S.a.

WKN: A2N9NP / Name: Pure Biologics S.a. / Stock / ? /

?
2.970%

Innovent Biologics, Inc.

WKN: A2N7N8 / Name: Innovent Biologics / Stock / Small Cap /

€9.20
-1.600%

Abcellera Biologics Inc.

WKN: A2QKXS / Name: Abcellera Biologics Inc. / Stock / ? /

€3.27
1.260%

Heat Biologics Inc.

WKN: A2QJR8 / Symbol: HBTX / Name: Heat Biologics / Stock / Biotechnology & Medical Research / Micro Cap /

€0.069
-24.860%

Wuxi Biologics Cayman Inc.

WKN: A2QJCN / Name: Wuxi Biologics / Stock / Mid Cap /

€4.03
-1.840%

Wuxi Biologics (cayman) Inc.

WKN: A2PQ3Q / Name: Wuxi Biologics (cayman) Inc. / Stock / ? /

?
3.250%

Synthetic Biologics Inc.

WKN: A3DMG6 / Symbol: SYN / Name: Synthetic Biologics / Stock / Biotechnology & Medical Research / Small Cap /

€0.12
-0.680%

Fibrobiologics Inc.

WKN: A3EP67 / Name: Fibrobiologics Inc. / Stock / ? /

€0.16
-14.140%

Theriva Biologics Inc.

WKN: A40MGC / Name: Theriva Biologics Inc. / Stock / ? /

€2.42
-

Fibrobiologics Inc.

WKN: A426UV / Name: Fibrobiologics Inc. / Stock / ? /

€3.74
-